Impact of disease-modifying therapies on humoral and cellular immune-responses following SARS-CoV-2 vaccination in MS patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: CTS Clinical and Translational Science 15 (2022) 7, 1606-1612
- Ereignis
-
Veröffentlichung
- (wo)
-
Münster
- (wer)
-
Universitäts- und Landesbibliothek Münster
- (wann)
-
2023
- Urheber
-
Trümpelmann, Susan
Schulte-Mecklenbeck, Andreas
Steinberg, Olga V.
Wirth, Timo
Fobker, Manfred
Lohmann, Lisa
Lünemann, Jan
Wiendl, Heinz
Gross, Catharina C.
Klotz, Luisa
- DOI
-
10.17879/39938516875
- URN
-
urn:nbn:de:hbz:6-89928468200
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:46 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Trümpelmann, Susan
- Schulte-Mecklenbeck, Andreas
- Steinberg, Olga V.
- Wirth, Timo
- Fobker, Manfred
- Lohmann, Lisa
- Lünemann, Jan
- Wiendl, Heinz
- Gross, Catharina C.
- Klotz, Luisa
- Universitäts- und Landesbibliothek Münster
Entstanden
- 2023
Ähnliche Objekte (12)
Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
Cellular and humoral SARS-CoV-2 vaccination responses in 192 adult recipients of allogeneic hematopoietic cell transplantation
Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination
Humoral Immunity in Immunosuppressed IBD Patients after the Third SARS-CoV-2 Vaccination: A Comparison with Healthy Control Subjects
SARS-CoV-2 specific cellular and humoral immunity after bivalent BA.4/5 COVID-19 vaccination in previously infected and non-infected individuals
Humoral protection to SARS-CoV2 declines faster in patients on TNF alpha blocking therapies
Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions
Vaccination against SARS-CoV-2: a human enhancement story
XV. Humoral-Pathologie
Routine Surveillance of SARS-CoV-2 Serostatus in Pediatrics Allows Monitoring of Humoral Response
Modifying adjuncts
Reactogenicity Correlates Only Weakly with Humoral Immunogenicity after COVID-19 Vaccination with BNT162b2 mRNA (Comirnaty®)
Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
Cellular and humoral SARS-CoV-2 vaccination responses in 192 adult recipients of allogeneic hematopoietic cell transplantation
Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination
Humoral Immunity in Immunosuppressed IBD Patients after the Third SARS-CoV-2 Vaccination: A Comparison with Healthy Control Subjects
SARS-CoV-2 specific cellular and humoral immunity after bivalent BA.4/5 COVID-19 vaccination in previously infected and non-infected individuals
Humoral protection to SARS-CoV2 declines faster in patients on TNF alpha blocking therapies
Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions
Vaccination against SARS-CoV-2: a human enhancement story
XV. Humoral-Pathologie
Routine Surveillance of SARS-CoV-2 Serostatus in Pediatrics Allows Monitoring of Humoral Response
Modifying adjuncts
Reactogenicity Correlates Only Weakly with Humoral Immunogenicity after COVID-19 Vaccination with BNT162b2 mRNA (Comirnaty®)
Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
Cellular and humoral SARS-CoV-2 vaccination responses in 192 adult recipients of allogeneic hematopoietic cell transplantation
Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination
Humoral Immunity in Immunosuppressed IBD Patients after the Third SARS-CoV-2 Vaccination: A Comparison with Healthy Control Subjects
SARS-CoV-2 specific cellular and humoral immunity after bivalent BA.4/5 COVID-19 vaccination in previously infected and non-infected individuals
Humoral protection to SARS-CoV2 declines faster in patients on TNF alpha blocking therapies
Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions
Vaccination against SARS-CoV-2: a human enhancement story
XV. Humoral-Pathologie
Routine Surveillance of SARS-CoV-2 Serostatus in Pediatrics Allows Monitoring of Humoral Response
Modifying adjuncts